Lacking Guidelines, HER2 Testing Brings Challenges To Breast Cancer Treatment In China
This article was originally published in PharmAsia News
Executive Summary
In a recent report, Kantar Health takes a deep dive into China’s breast cancer market, where cost considerations play a larger role than in the West.